3CLpro Protease Inhibitor Compound for Coronavirus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coronavirus infections, particularly those caused by SARS-CoV-2, lack effective inhibitors for the 3CLPro protease, which is crucial for virus replication and evasion of the host's immune response.
Innovation Solution
Development of a compound represented by formula (I) or its isomers or pharmaceutically acceptable salts, which acts as a 3CLPro protease inhibitor. The compound has a specific structural arrangement that includes various rings and functional groups, allowing it to effectively target and inhibit the 3CLPro enzyme.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for coronavirus infections, then current standard care can be provided, but effective inhibition of 3CLPro protease is not achieved
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of the inhibitor compound, including substituting different groups at positions R1-R6 and adjusting the core scaffold structure. This allows optimization of binding affinity and inhibitory activity against 3CLPro protease, transforming an ineffective treatment approach into an effective one through chemical parameter optimization.
Solution Approach 2:
The invention employs composite material principles by creating a complex molecular structure that combines multiple functional groups and structural motifs within a single inhibitor compound. The composite nature of the molecule allows simultaneous interaction with multiple residues in the protease active site, achieving effective inhibition that simple single-function compounds cannot accomplish.
2Reliability
If a compound with specific structural arrangement is developed to target 3CLPro, then inhibitory effect is improved, but structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core scaffold structure and multiple substitutable groups (R1-R6) at specific positions. This modular segmentation allows independent optimization of each segment's contribution to binding affinity while maintaining overall manageability of the complex structure through systematic variation of individual components.
Solution Approach 2:
The invention implements local quality by assigning specific functional characteristics to different regions of the molecule. Different substituents at positions R1-R6 provide localized interactions with specific residues in the protease active site, allowing the complex structure to be understood and designed through the sum of local interaction qualities rather than as an undifferentiated whole.
Data Source
AI summary
Provided are a 3Clpro protease inhibitor, a pharmaceutical composition containing the compound of formula (I), and a method for treating coronavirus by using the compound.